Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours
Field | Value | Language |
dc.contributor.author | Kanjanapan, Yada | en_AU |
dc.contributor.author | Blinman, Prunella | en_AU |
dc.contributor.author | Underhill, Craig | en_AU |
dc.contributor.author | Karikios, Deme | en_AU |
dc.contributor.author | Segelov, Eva | en_AU |
dc.contributor.author | Yip, Desmond | en_AU |
dc.date.accessioned | 2021-07-06T23:34:20Z | |
dc.date.available | 2021-07-06T23:34:20Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/2123/25591 | |
dc.description.abstract | People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed. | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours | en_AU |
dc.type | Article | en_AU |
dc.identifier.doi | 10.1111/imj.15339 |
Associated file/s
There are no files associated with this item.
Associated collections